Brought to you by 
Endo strengthens pain portfolio through Penwest acquisition
24 Sep 2010
Executive Summary
Several months after acquiring Medical Enterprises Europe BV and HealthTronics to diverse its portfolio into medical devices, Endo Pharmaceuticals Holdings Inc. (branded and generic products) is back into pharma dealmaking again, spending $159.7mm for Penwest Pharmaceuticals Co., a public company specializing in extended-release drug delivery. Endo will pay $5 (a 39% premium) for each of Penwest's 32mm shares outstanding.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Endo strengthens pain portfolio through Penwest acquisition
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice